Nautilus Biotechnology annual capital expenditures (capex)
2020
2021
2022
2023
2024
2025
Nautilus Biotechnology Capital Expenditures (CapEx) Growth & History (NAUT)
Nautilus Biotechnology's capital expenditures (capex) was $1.3M for fiscal 2025.
View full Nautilus Biotechnology company overviewNautilus Biotechnology annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.3M | −$845,000 | −39.82% |
| 2024 | 2024-12-31 | $2.1M | −$320,000 | −13.10% |
| 2023 | 2023-12-31 | $2.4M | $118,000 | +5.08% |
| 2022 | 2022-12-31 | $2.3M | $55,000 | +2.42% |
| 2021 | 2021-12-31 | $2.3M | $1.3M | +146.36% |
| 2020 | 2020-12-31 | $921,000 | — | — |
Nautilus Biotechnology quarterly capital expenditures (capex)
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $454,000 | $58,000 | +14.65% |
| Q1 2026 | 2026-03-31 | $510,000 | $291,000 | +132.88% |
| Q4 2025 | 2025-12-31 | $244,000 | −$10,000 | −3.94% |
| Q3 2025 | 2025-09-30 | $418,000 | −$291,000 | −41.04% |
| Q2 2025 | 2025-06-30 | $396,000 | −$116,000 | −22.66% |
| Q1 2025 | 2025-03-31 | $219,000 | −$428,000 | −66.15% |
| Q4 2024 | 2024-12-31 | $254,000 | −$159,000 | −38.50% |
| Q3 2024 | 2024-09-30 | $709,000 | −$165,000 | −18.88% |
| Q2 2024 | 2024-06-30 | $512,000 | $49,000 | +10.58% |
| Q1 2024 | 2024-03-31 | $647,000 | −$45,000 | −6.50% |
| Q4 2023 | 2023-12-31 | $413,000 | $184,000 | +80.35% |
| Q3 2023 | 2023-09-30 | $874,000 | −$89,000 | −9.24% |
| Q2 2023 | 2023-06-30 | $463,000 | −$188,000 | −28.88% |
| Q1 2023 | 2023-03-31 | $692,000 | $211,000 | +43.87% |
| Q4 2022 | 2022-12-31 | $229,000 | −$757,000 | −76.77% |
| Q3 2022 | 2022-09-30 | $963,000 | $693,000 | +256.67% |
| Q2 2022 | 2022-06-30 | $651,000 | $120,000 | +22.60% |
| Q1 2022 | 2022-03-31 | $481,000 | −$1,000 | −0.21% |
| Q4 2021 | 2021-12-31 | $986,000 | — | — |
| Q3 2021 | 2021-09-30 | $270,000 | $8,000 | +3.05% |
| Q2 2021 | 2021-06-30 | $531,000 | — | — |
| Q1 2021 | 2021-03-31 | $482,000 | — | — |
| Q3 2020 | 2020-09-30 | $262,000 | — | — |
Nautilus Biotechnology capital expenditures (capex) trends
Over the last five fiscal years, Nautilus Biotechnology's capital expenditures (capex) increased from $921,000 to $1.3M, a change of $356,000. The latest reported quarter, Q2 2026, shows $454,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nautilus Biotechnology source filings ↗